ポシミールの薬剤に関する洞察と市場予測：2032年

浸潤用ポシミール（ブピバカイン液）は、660mgのブピバカイン基剤の強さと革新的なSABERプラットフォーム技術を組み合わせた新規かつ独自の製品であり、成人において3日間にわたり非オピオイド性局所鎮痛薬の持続的な投与を可能にします。ポシミールは、承認された他の単回投与徐放性ブピバカイン製剤よりも多くのブピバカインを含有しています。ポシミールは手術終了時に関節鏡で直接確認しながら肩峰下腔に投与され、72時間以上持続的にブピバカインを放出します。Durect社はポシミールの商業化権をライセンシングするパートナー候補と協議中であり、ポシミールはDurectが世界の権利を保有しています。

当レポートでは、米国におけるポシミール市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性疼痛におけるポシミールの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ポシミール市場評価

• 急性疼痛におけるポシミールの市場展望
• 米国の分析

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: POSIMIR, Clinical Trial Description, 2023
• Table 2: POSIMIR, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: POSIMIR Market Size in the US, in USD million (2019-2032)

List of Figures

• Figure 1: POSIMIR Market Size in the United States, USD million (2019-2032)

"POSIMIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about POSIMIR for acute pain in the United States. A detailed picture of the POSIMIR for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the POSIMIR for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

POSIMIR (bupivacaine solution) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. POSIMIR contains more bupivacaine than any other approved single-dose sustained-release bupivacaine product. POSIMIR is administered into the subacromial space under direct arthroscopic visualization at the end of the surgery, where it continuously releases bupivacaine for 72 hours or more. Durect is discussing with potential partners licensing commercialization rights to POSIMIR, for which Durect holds worldwide rights.

Dosage and administration

The recommended dose is a 5 mL single-dose vial, 660 mg/5 mL (132 mg/mL).

Mechanism of action

Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve by slowing the propagation of the nerve impulse and reducing the rate of the rising action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the POSIMIR description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POSIMIR research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted sales of POSIMIR for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for POSIMIR in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Analytical Perspective by DelveInsight

In-depth POSIMIR Market Assessment

This report provides a detailed market assessment of POSIMIR for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

POSIMIR Clinical Assessment

The report provides the clinical trials information of POSIMIR for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for acute pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in acute pain.
• Our in-depth analysis of the forecasted sales data of POSIMIR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of POSIMIR?
• What is the clinical trial status of the study related to POSIMIR in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for acute pain?
• What is the forecasted market scenario of POSIMIR for acute pain?
• What are the forecasted sales of POSIMIR in the United States?
• What are the other emerging products available and how are these giving competition to POSIMIR for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. POSIMIR Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. POSIMIR Market Assessment

• 5.1. Market Outlook of POSIMIR in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of POSIMIR in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options